The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Novel therapies and pitfalls in MPNs
Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, outlines novel therapy approaches and pitfalls in the treatment of myeloproliferative neoplasms (MPNs). Dr Yacoub explores the use of JAK inhibitors for this indication as well as ongoing clinical trials investigating combination therapies for MPNs. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
